March 14, 2012
News Release

The entire staff at the Mesothelioma Research Foundation of America stops and takes a deliberate moment to recognize and send a sincere thanks to the JOHNS for their donation of $5,000 designated for mesothelioma cancer research. The JOHNS event is held annually to honor a dear deceased friend, John S. Lyons, by acknowledging today's Labor Leader of the Year as well as raise money for cancer research and other local charities.

read more...


November 14, 2011
News Release

Today, Dr. Parkash Gill announced that Veglin is not released yet to restart it's Phase 2 Clinical Trials, and continues to wait for FDA approval. Dr. Gill is working hard to get Veglin into Phase 2 and also working diligently to get EPH-B4 into Phase 1 Clinical Trials.

Learn about Veglin at this MesoRFA link: read more...

And learn about participating in a clinical trial at this MesoRFA link:
Clinical trials, read more...
Veglin trials, read more...
Veglin treatment, read more...


Bring your questions to Dr. Gill: click HERE

September 10, 2011
The JOHNS event is held to honor an old friend, John S. Lyons, by recognizing today's Labor Leader of the Year and to raise money for cancer research and local charities. This year the Teamsters International Vice President, Randy Cammack, was given the prestigious award of Labor Leader of the Year.

read more...


Mar 19, 2011
National Asbestos Awareness Week will begin the first week of April. This is an important opportunity and the right time to help increase public awareness about the dangers of asbestos exposure and the mesothelioma treatments available for the cancer caused by asbestos particle inhalation. Now is the time to rise up and let patients afflicted with this dreadful disease know we stand unified with concern for their medical condition and are willing to support mesothelioma treatments like Vegliin.

read more...


DONATIONS for cancer cure

100 percent of all proceeds received are going to the USC Norris Comprehensive Cancer Medical Center in Los Angeles to support the FDA Phase III of Dr. Gill's clinical trials. These trials are for Veglin, a mesothelioma cancer treatment. Veglin manipulates the blood vessels to starve a malignant tumor while alleviating fluid build up in the lungs

Support the hope in this research and click HERE


Patient Assistance Programs are offered by many pharmaceutical manufacturers to help pay for medications. These offers are sometimes called Indigent Drug Programs. Use our link just following, and learn whether a specific drug might be available at reduced cost or for free.

Drug Assistance Programs: click HERE

At the Mesothelioma Research Foundation of America, you can call toll free (800) 909-Meso (6376) to talk with one of our Cancer Information Specialists who will gladly look up the phone numbers or the web site of the pharmaceutical company that makes the drug you are using


Find the lastest Mesothelioma clinical trials: click HERE

To ask Dr. Gill a question: click HERE

Help this Foundation and click HERE


Cancer imposes heavy economic burdens on a cancer patients and family members alike. Resources are available for individuals who do not have health insurance or who need financial assistance to cover health care costs. Our listing will help you find Government agencies, private organizations, and programs that are designed to provide assistance for a cancer patient and their family.

Financial help for cancer patients: click HERE

At the Mesothelioma Research Foundation of America, you can call toll free (800) 909-Meso (6376) to talk with one of our Cancer Information Specialists who will gladly look up the phone numbers or the web site of organizations that provide financial assistance.

Bring your questions to Dr. Gill: click HERE

Help grow the Foundation and cancer-cure research: click HERE

Pause
Resume

Clinical Trials Status

On November 14, 2011, Dr. Parkash Gill announced that Veglin is not released yet to restart it's Phase 2 Clinical Trials, and the project continues to wait for FDA approval. Dr. Gill is working hard to restart Veglin within Phase 2 and is also working diligently to get EPH-B4 into Phase I Clinical Trials.

Please use our FaceBook link to obtain your FREE copy of our eBook that teaches you 10 easy steps on how to find and choose a clinical trial for Mesothelioma and how to prepare for it!

Ask Dr. Gill about your specific mesothelioma issues here: Ask Dr. Gill

Learn more about Veglin at this cancer research link: read more...

In addition to the eBook found at our Facebook fan page, also learn more about clinical trials from these links:


THE FOUNDATION

The Mesothelioma Research Foundation of America has a mission: fund research that will lead to the quickest cure for mesothelioma. Mesothelioma is a cancer of the lining of the lungs caused by asbestos exposure. This cancer disease had few treatment options until this Foundation and Dr. Parkash Gill's work created better treatment options. Today, the future looks more hopeful for additional improved treatment options available to those stricken by this cancer.

James W. Kellogg, Jerry Neil Paul, Elizabeth Paul and Dr. Parkash Gill, M.D.
The Foundation Board Members from the left are: James W. Kellogg, Jerry Neil Paul, Elizabeth Ann Paul and Dr. Parkash Gill, M.D. These are respectively the United Association International Representative, Founding Director, Executive Director and Chairman of the Medical Advisory Board.

 

The Mesothelioma Research Foundation of America began funding research for a cure in 2001 with the opening of the Mesothelioma Laboratory at USC Norris Comprehensive Cancer Medical Center in Los Angeles under the supervision of Dr. Parkash Gill.

Dr. Gill is a board certified oncologist and hematologist who has received FDA approval from the U.S. Government to do Clinical Trials on a mesothelioma treatment drug called Veglin. We believe there is great promise and hope in Veglin and the Mesothelioma Research Foundation of America has funded 100% of Dr. Gill's research.

Veglin proved successful in Phase I and Phase II clinical trials. Many are very hopeful for the possibilities of a more effective cancer treatment compared to what presently is available for mesothelioma victims. We are currently waiting for further FDA approval to move into Phase III clinical trials.

Top of Page